Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Larry Liebman who started this subject	11/10/2003 1:13:18 PM
From: Ian@SI	Read Replies (2) of 824

I fail to understand why ALXN finds a prospective endpoint with a p-value of .096 encouraging even though the p-value for the primary endpoint was much better and is disappointing! The encouraging effect of pexelizumab on postoperative morbidity and mortality appeared to persist, as pexelizumab was associated with a 25% reduction in 90 day mortality (placebo 4.8% vs. pexelizumab 3.6%, p=.096), an important prospectively defined secondary endpoint.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next